Cargando…
Drug targets for corona virus: A systematic review
The 2019-novel coronavirus (nCoV) is a major source of disaster in the 21(th) century. However, the lack of specific drugs to prevent/treat an attack is a major need at this current point of time. In this regard, we conducted a systematic review to identify major druggable targets in coronavirus (Co...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074424/ https://www.ncbi.nlm.nih.gov/pubmed/32201449 http://dx.doi.org/10.4103/ijp.IJP_115_20 |
_version_ | 1783506830103674880 |
---|---|
author | Prajapat, Manisha Sarma, Phulen Shekhar, Nishant Avti, Pramod Sinha, Shweta Kaur, Hardeep Kumar, Subodh Bhattacharyya, Anusuya Kumar, Harish Bansal, Seema Medhi, Bikash |
author_facet | Prajapat, Manisha Sarma, Phulen Shekhar, Nishant Avti, Pramod Sinha, Shweta Kaur, Hardeep Kumar, Subodh Bhattacharyya, Anusuya Kumar, Harish Bansal, Seema Medhi, Bikash |
author_sort | Prajapat, Manisha |
collection | PubMed |
description | The 2019-novel coronavirus (nCoV) is a major source of disaster in the 21(th) century. However, the lack of specific drugs to prevent/treat an attack is a major need at this current point of time. In this regard, we conducted a systematic review to identify major druggable targets in coronavirus (CoV). We searched PubMed and RCSB database with keywords HCoV, NCoV, corona virus, SERS-CoV, MERS-CoV, 2019-nCoV, crystal structure, X-ray crystallography structure, NMR structure, target, and drug target till Feb 3, 2020. The search identified seven major targets (spike protein, envelop protein, membrane protein, protease, nucleocapsid protein, hemagglutinin esterase, and helicase) for which drug design can be considered. There are other 16 nonstructural proteins (NSPs), which can also be considered from the drug design perspective. The major structural proteins and NSPs may serve an important role from drug design perspectives. However, the occurrence of frequent recombination events is a major deterrent factor toward the development of CoV-specific vaccines/drugs. |
format | Online Article Text |
id | pubmed-7074424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-70744242020-03-20 Drug targets for corona virus: A systematic review Prajapat, Manisha Sarma, Phulen Shekhar, Nishant Avti, Pramod Sinha, Shweta Kaur, Hardeep Kumar, Subodh Bhattacharyya, Anusuya Kumar, Harish Bansal, Seema Medhi, Bikash Indian J Pharmacol Systematic Review The 2019-novel coronavirus (nCoV) is a major source of disaster in the 21(th) century. However, the lack of specific drugs to prevent/treat an attack is a major need at this current point of time. In this regard, we conducted a systematic review to identify major druggable targets in coronavirus (CoV). We searched PubMed and RCSB database with keywords HCoV, NCoV, corona virus, SERS-CoV, MERS-CoV, 2019-nCoV, crystal structure, X-ray crystallography structure, NMR structure, target, and drug target till Feb 3, 2020. The search identified seven major targets (spike protein, envelop protein, membrane protein, protease, nucleocapsid protein, hemagglutinin esterase, and helicase) for which drug design can be considered. There are other 16 nonstructural proteins (NSPs), which can also be considered from the drug design perspective. The major structural proteins and NSPs may serve an important role from drug design perspectives. However, the occurrence of frequent recombination events is a major deterrent factor toward the development of CoV-specific vaccines/drugs. Wolters Kluwer - Medknow 2020 2020-03-11 /pmc/articles/PMC7074424/ /pubmed/32201449 http://dx.doi.org/10.4103/ijp.IJP_115_20 Text en Copyright: © 2020 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Systematic Review Prajapat, Manisha Sarma, Phulen Shekhar, Nishant Avti, Pramod Sinha, Shweta Kaur, Hardeep Kumar, Subodh Bhattacharyya, Anusuya Kumar, Harish Bansal, Seema Medhi, Bikash Drug targets for corona virus: A systematic review |
title | Drug targets for corona virus: A systematic review |
title_full | Drug targets for corona virus: A systematic review |
title_fullStr | Drug targets for corona virus: A systematic review |
title_full_unstemmed | Drug targets for corona virus: A systematic review |
title_short | Drug targets for corona virus: A systematic review |
title_sort | drug targets for corona virus: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074424/ https://www.ncbi.nlm.nih.gov/pubmed/32201449 http://dx.doi.org/10.4103/ijp.IJP_115_20 |
work_keys_str_mv | AT prajapatmanisha drugtargetsforcoronavirusasystematicreview AT sarmaphulen drugtargetsforcoronavirusasystematicreview AT shekharnishant drugtargetsforcoronavirusasystematicreview AT avtipramod drugtargetsforcoronavirusasystematicreview AT sinhashweta drugtargetsforcoronavirusasystematicreview AT kaurhardeep drugtargetsforcoronavirusasystematicreview AT kumarsubodh drugtargetsforcoronavirusasystematicreview AT bhattacharyyaanusuya drugtargetsforcoronavirusasystematicreview AT kumarharish drugtargetsforcoronavirusasystematicreview AT bansalseema drugtargetsforcoronavirusasystematicreview AT medhibikash drugtargetsforcoronavirusasystematicreview |